In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Savara Inc (NASDAQ: SVRA), with a price target of $22. The company’s shares closed yesterday at $11.26.
According to TipRanks.com, Fein is a 4-star analyst with an average return of 4.7% and a 47.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
Currently, the analyst consensus on Savara Inc is a Strong Buy with an average price target of $29, representing a 157.5% upside. In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $25 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $17.19 and a one-year low of $5.07. Currently, Savara Inc has an average volume of 266.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.
